A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Conditions: Prostate Cancer Patients Treated by Radiotherapy

Interventions: Biological: aglatimagene besadenovec + valacyclovir

Sponsors: Candel Therapeutics, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 13, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments